Vaxart (OTCMKTS:VXRT) Stock Rating Upgraded by Zacks Research

Key Points

• Zacks Research upgraded Vaxart to a “hold” rating in a report released Thursday, signaling a more neutral view on the stock.
• Vaxart shares were trading at $0.55, below both its 50-day and 200-day moving averages, with a market cap of about $132.6 million.
• The company’s latest quarterly results showed EPS of $0.02, matching estimates, but revenue of $39.23 million came in below the $50.50 million consensus forecast.

Vaxart (OTCMKTS:VXRT - Get Free Report) was upgraded by stock analysts at Zacks Research to a "hold" rating in a report released on Thursday,Zacks.com reports.

Vaxart Price Performance

OTCMKTS VXRT opened at $0.55 on Thursday. The company has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $0.62. The firm has a market capitalization of $132.59 million, a price-to-earnings ratio of 3.64 and a beta of 1.09. Vaxart has a 52-week low of $0.30 and a 52-week high of $0.84.

Vaxart (OTCMKTS:VXRT - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.02 EPS for the quarter, meeting analysts' consensus estimates of $0.02. Vaxart had a net margin of 14.51% and a return on equity of 61.43%. The firm had revenue of $39.23 million for the quarter, compared to the consensus estimate of $50.50 million. On average, analysts predict that Vaxart will post -0.68 EPS for the current year.

Institutional Trading of Vaxart

A number of institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. raised its stake in shares of Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company's stock worth $107,000 after purchasing an additional 34,075 shares in the last quarter. Invesco Ltd. grew its stake in shares of Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock valued at $60,000 after buying an additional 70,568 shares in the last quarter. Creative Planning bought a new stake in shares of Vaxart in the 2nd quarter valued at approximately $33,000. Goldman Sachs Group Inc. acquired a new position in Vaxart in the first quarter worth approximately $31,000. Finally, Jones Financial Companies Lllp increased its holdings in Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after buying an additional 478,111 shares during the last quarter. Institutional investors and hedge funds own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.